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Introduction
Coronary revascularization is an important part of 
the treatment of patients with coronary artery disease. 
However, a significant proportion of patients are char-
acterized by high-risk features. Many of these patients 
are referred for high-risk percutaneous coronary inter-
ventions (PCIs) due to the extremely high risk of sur-
gery. To support such procedures and to facilitate the 
care of high-risk patients, percutaneous left ventricular 
assist devices (pLVAD) were developed. Due to con-
founding data and downgraded guidelines for use of 
the intra-aortic balloon pump (IABP), especially in car-
diogenic shock caused by myocardial infarction (MI), 
there is currently growing interest in pLVAD [1, 2]. The 
use of pLVAD during high-risk PCI in Europe varies from 
country to country mainly due to different reimburse-
ment policies. 
Aim
Due to growing interest in pLVAD support during 
high-risk PCIs in Poland and Europe, we aim to present 
our initial experience with the Impella CP system during 
high-risk PCIs.
Material and methods
The study is a  prospective registry of all patients 
treated with the Impella CP (ABIOMED Inc., Danvers, MA, 
USA) in Poland. Data are collected based on a dedicat-
ed questionnaire. The registry is currently conducted 
in six high-volume PCI centers. All procedures are per-
formed with highly experienced operators and are fully 
supported by company (distributor in Poland) staff either 
on site for elective procedures or with phone support for 
emergency usage. Also two types of training courses are 
provided for physicians, nurses and technicians: one for 
staff performing the procedure with the Impella and the 
second for staff taking care of patients after the proce-
dure. This is important for the first cases when this new 
technology is implemented.
The results are presented as the number of patients 
or mean ± standard deviation where applicable. 
Results
A total of 10 patients were treated with Impella CP 
support from April 2013 to August 2015 (four in 2013/14 
and six in 2015). In all cases except one, the Impella CP 
was used during high-risk elective PCI, and the present 
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analysis is focused on those nine patients. In this one ex-
cluded case, the Impella CP was used due to an acute MI 
complicated with cardiogenic shock. Baseline character-
istics of enrolled patients are summarized in Table I. All 
patients were men with a mean age of 73 ±11 years and 
mean left ventricular ejection fraction of 32 ±8%. The 
baseline risk profile of enrolled patients was rather high, 
with previous revascularization, previous MI and chronic 
kidney disease in half of the patients. In the majority of 
cases the left main coronary artery was the target vessel 
for PCI (Table I). All patients received drug-eluting stents 
during PCI. In all cases the device was implanted under 
the supervision of the company representative on site. In 
all cases the femoral access with a 14 F Oscor introducer 
and Abiomed 0.018 guidewire was used. In two cases 
the Impella CP was implanted with surgeon support and 
in seven with the wire insertion method. The Automated 
Impella Controller was used in all patients with Autoflow 
and P-level configuration in 5 and 4 patients respectively. 
In all cases support with the Impella CP was continued 
until the end of the procedure. Surgical closure was used 
in four patients and an arterial closure device in 5 pa-
tients (four with Perclose ProGlide (Abbott Vascular, CA, 
USA), one with AngioSeal (St. Jude Medical, MN, USA)). 
Thirty-day outcomes of patients treated for high-risk 
elective PCI were good, with no death during follow-up. 
Only in 1 patient was a small hematoma at the site of 
device insertion noted.
Discussion
In our initial series we found the use of the Impella CP 
during high-risk PCI to be feasible and safe. 
Patients with extensive coronary artery disease, de-
pressed left ventricular ejection fraction, hemodynamic 
instability and multiple comorbidities are at high risk 
for coronary revascularization procedures. During recent 
years due to population aging in Europe there is a grow-
ing number of such high-risk elderly patients who are 
candidates for revascularization. Coronary artery bypass 
grafting with full revascularization seems to be a  pre-
ferred option, but often due to high surgical risk such 
patients are referred for percutaneous revascularization 
[3, 4]. In such a case the benefit of percutaneous revas-
cularization is expected; however, the risk of periproce-
dural events is very high. Therefore there is a strong clin-
ical need of periprocedural support. Formerly, IABP was 
used as a PCI support mainly for patients with MI and/
or cardiogenic shock. It was used less often during elec-
tive high-risk procedures. However, according to current 
data the value of IABP is questionable [1, 2]. To overcome 
the limitations of IABP and to reduce the risk of PCIs in 
such patients, the strategy of procedural support with 
pLVAD technology was proposed. The Impella technology 
is an axial flow, rotary pump built on a 9 Fr catheter. For 
PCI support, the device is deployed via femoral access 
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in a retrograde way across the aortic valve. In our series 
of patients the Impella CP with higher blood flow was 
used. The Impella CP theoretically provides nonpulsatile 
forward blood flow of up to 4.0 l/min (max speed 46 000 
rpm) which is independent of cardiac rhythm. However, 
there is native heart pulsatile flow creating pulsatility of 
blood flow through the device. That is why the motor cur-
rent maximum is reached during systole and is associated 
with higher flows and higher pump speeds. So pump flow 
is the highest during systole and lowest during diastole 
[5]. In our series of cases in five patients the “Autoflow” 
and in four the “P-level” pump configuration was used. 
Autoflow is a fully automated program in which the de-
vice provides maximal support for the particular patient, 
and there is no need for operator intervention. This may 
be a reasonable option for initial cases. P-level configu-
ration is a manual mode in which a support level from 
P0 to P9 may be selected, but some experience is neces-
sary to use such a protocol. This mode is also useful for 
device removal, especially for cardiogenic shock patients 
when support should be gradually reduced (like in IABP) 
before termination. Importantly, the device is designed 
for a fully percutaneous femoral approach with no need 
of surgical preparation. However, in the presented results 
surgical vascular access was used in 2 cases in one study 
center, but it was according to the local policy for new 
device introduction rather than a systemic approach. In 
4 cases surgical vessel closure was performed for the 
same reason. For high-risk PCI support, vascular access 
and vascular closure after Impella usage may be used ful-
ly percutaneously by an operator who is experienced in 
this technology. For initial cases, surgical back-up may be 
a reasonable option. In Poland, the first procedure of per-
cutaneous Impella support (Impella 2.5 device) was per-
formed in the Institute of Cardiology in Krakow (K. Żmud-
ka, T. Pawelec) in 2007. In the PROTECT II study, Impella 
technology was shown to be associated with improved 
clinical outcome at 90 days as compared to IABP in pa-
tients undergoing high-risk PCI [6]. In a sub-analysis of 
PROTECT II the benefit of Impella (compared to IABP) was 
observed in patients with three-vessel coronary artery 
disease and impaired left ventricular function [7]. The 
PROTECT II study was based on the Impella 2.5 device. 
In the Europella Registry on high-risk patients with a lo-
gistic EuroSCORE of about 15%, the 30-day death rate 
was 5.5%, the vascular complication rate was 4%, and 
device malfunction was not observed, showing Impella 
2.5 periprocedural support to be safe and feasible [8]. 
Similarly, in the USpella registry the overall angiographic 
success was 99%, the survival rate was 96% at 30 days 
and 88% at 12 months, and in 3.4% of patients transfu-
sion was required due to access site bleeding [9]. Despite 
the higher risk of the patients included in the USpella 
registry as compared to those enrolled in the random-
ized trial (PROTECT II), clinical outcomes of registry “real- 
life” patients appeared to be favorable [10]. Operator’s 
experience seems to be important for patient outcomes 
when using Impella support during high-risk PCI. In the 
prespecified subgroup analysis of the PROTECT II study 
in which the outcomes were evaluated after excluding 
the first Impella and IABP patients at each site, a trend 
toward higher rates of major adverse cardiovascular 
events at 30 days was observed for the subgroup of the 
first versus the remaining Impella 2.5 patients. Impor-
tantly, after exclusion of the first patient in each group, 
the major adverse cardiovascular event rate for the Im-
pella 2.5 was significantly lower compared to IABP at 
90 days (38% vs. 50%; p = 0.029) [11]. This may suggest 
the presence of a learning curve associated with the use 
of the Impella 2.5. So it may be better to perform the first 
cases with the supervision of an experienced proctor. 
This fact also raises a question about the hub-spoke con-
cept for PCI procedures with Impella support. It may be 
reasonable to establish reference centers to increase the 
team experience and improve the results by cumulating 
the usage of the device in a limited number of centers. It 
should be underlined that such a scenario is possible in 
planned PCI procedures but probably not in patients with 
cardiogenic shock, who are also a target population for 
pLVAD support [12].
The presented strategy describes the so-called “pro-
tected PCI”. In such an approach, complex PCI procedures 
in high-risk patients may be performed with a full range 
of devices and techniques due to the stable hemodynam-
ic status driven by the pLVAD support. This may improve 
patients’ outcome. However, the penetration of pLVAD is 
dependent on the reimbursement policy. In Poland this 
procedure is currently not reimbursed, and it is fully cov-
ered by hospital funds. Impella usage during high-risk PCI 
is reimbursed in many European countries and the USA.
It is worth mentioning that besides LV support it is 
also possible to provide right ventricle support with the 
Impella RP system. It may be used in patients with car-
diogenic shock due to RV failure and may be helpful ei-
ther in isolation or in combination with the Impella CP for 
patients with shock [13].
Based on previous studies as well as on the presented 
experience, the Impella CP seems to be feasible and safe 
as circulatory support during high-risk PCI procedures.
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